Genetic-epigenetic targets for PCOS-associated diabesity.

Polycystic ovary syndrome (PCOS) and diabesity are interconnected endocrine disorders driven by a complex interplay of genetic, epigenetic and environmental factors. This review examines the molecular crosstalk between PCOS and diabesity, focusing on shared pathophysiological pathways and their regulatory mechanisms. Key genetic predispositions (such as polymorphisms) associated with insulin resistance, androgen biosynthesis and inflammation have been conferred that could significantly contribute to their overlapping phenotypes. Additionally, epigenetic modifications, including DNA methylation, histone modifications and non-coding RNAs, have been discussed that further participate in regulation of gene expression and metabolic dysfunction. Understanding these molecular interconnections highlights crucial signaling nodes that can serve as potential therapeutic targets. This review underscores emerging avenues for drug development, aiming to mitigate disease progression and improve patient outcomes.